Association between SUR1 Ser1369Ala polymorphism and the efficacy of sulfonylurea
- VernacularTitle:SUR1 Ser1369Ala多态性与磺脲类药物疗效的相关性
- Author:
Yi YANG
;
Limin GUO
;
Jinkui YANG
- Publication Type:Journal Article
- Keywords:
type 2 diabetes;
sulfonylurea receptor;
gene polymorphism;
sulfonylurea drug
- From:
Basic & Clinical Medicine
2006;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association between a missense mutation (T/G, Ser 1369 Ala) in exon 33 of sulfonylurea receptor 1(SUR1) gene in type 2 diabetes patients and the glucose-lowering effect of Gliclazide. Methods One hundred and four type 2 diabetes patients were selected and orally administered with Gliclazide for 56 days. Venous fasting plasma glucose levels (FPG), plasma glucose levels half an hour after taking 75 g glucose (OGH) and two hours (OGT) after taking Gliclazide were measured. Ser1369Ala polymorphism genotypes(TT, TG, GG) of SUR1 gene were determined by Taqman method. The glucose-lowering effect of Gliclazide was compared among different groups. If FPG was reduced more than 20%, we define it as effective. People whose blood sugar level was effectively reduced and not significantly reduced were compared to find whether their genotype groups were different.Results The change of FPG,OGH and OGT on day 1 and day 57 among TT,TG and GG genotype groups had no statistically significant difference. There was no statistically significant difference of the efficacy of Gliclazide in recessive model (TT+TG vs GG). The combination of TG and GG was more effective in reducing blood sugar level than TT. Conclusion Patients carrying one or two copies of the G allele were more sensitive to Gliclazide than patients carrying T allele.
